(a) Excludes 19 participants who did not answer the question of vaccination status and were not included in the analysis (b) “Vaccinated” and “ASAP” groups were combined for the analysis (c) Excludes 12 participants who returned but did not answer the question of vaccination status.</p
<p>Details on study exclusions and population analyzed to study the association between HPV vaccinat...
<p>Ten (10) out of 38 participants that were screened for this study, were randomized to receive eit...
This is the status of COVID-19 vaccination including immediate health consequences among the respond...
(a) Excludes 19 participants who did not answer the question of vaccination status and were not incl...
Participant demographics, infection and vaccine history in the saRNA (COVAC1) and non-saRNA particip...
<p>IQR: Interquartile range, NA: not applicable.</p>a<p>Not vaccinated according to vaccine records ...
<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one ...
Individuals were considered fully vaccinated based on vaccine registry (WIR/WEDSS) data if the regis...
Comparisons of the vaccine types after the COVID-19 vaccine among sera of participants groups accord...
Level of CTLA-4 among sera of participants groups with or without COVID-19 according to type of vacc...
(A) after the first dose, (B) after the second dose. A statistical analysis of the adverse effects a...
*Both sex assigned at birth and current gender identity were self-reported by participants. One part...
<p>Vaccine effectiveness is 92.9% and corresponding 95% confidence intervals are (66.6%, 98.5%).</p>...
<p>Subject enrollment, exclusions and outcomes for two prospective cohorts, post-smallpox and annual...
<p>AD = atopic dermatitis; n = number of subjects in the specified category; FAS = full analysis set...
<p>Details on study exclusions and population analyzed to study the association between HPV vaccinat...
<p>Ten (10) out of 38 participants that were screened for this study, were randomized to receive eit...
This is the status of COVID-19 vaccination including immediate health consequences among the respond...
(a) Excludes 19 participants who did not answer the question of vaccination status and were not incl...
Participant demographics, infection and vaccine history in the saRNA (COVAC1) and non-saRNA particip...
<p>IQR: Interquartile range, NA: not applicable.</p>a<p>Not vaccinated according to vaccine records ...
<p>Of 242 screened volunteers, 120 subjects were assessed eligible for enrollment, allocated to one ...
Individuals were considered fully vaccinated based on vaccine registry (WIR/WEDSS) data if the regis...
Comparisons of the vaccine types after the COVID-19 vaccine among sera of participants groups accord...
Level of CTLA-4 among sera of participants groups with or without COVID-19 according to type of vacc...
(A) after the first dose, (B) after the second dose. A statistical analysis of the adverse effects a...
*Both sex assigned at birth and current gender identity were self-reported by participants. One part...
<p>Vaccine effectiveness is 92.9% and corresponding 95% confidence intervals are (66.6%, 98.5%).</p>...
<p>Subject enrollment, exclusions and outcomes for two prospective cohorts, post-smallpox and annual...
<p>AD = atopic dermatitis; n = number of subjects in the specified category; FAS = full analysis set...
<p>Details on study exclusions and population analyzed to study the association between HPV vaccinat...
<p>Ten (10) out of 38 participants that were screened for this study, were randomized to receive eit...
This is the status of COVID-19 vaccination including immediate health consequences among the respond...